

2 November 2017

Meluka Health Appoints Leading Bee And Honey Advisor

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on Meluka Health, a Company it is acquiring a 50% interest in.

Appointment of David Rudd

Meluka Health has appointed Dr. David Rudd as a special advisor to the Meluka Health board. Dr Rudd will be providing specialist advice on product development, evaluation and efficacy for a range of Meluka Honey products incorporating;

- Medicinal/Therapeutic Honey – ingestible therapeutic honey
- Topical Honey Balm – for burns and wound application
- Bee Tonic – bee health product

These products are derived from an old growth Melaleuca tea tree plantation located in northern NSW. In addition, Dr. Rudd will assist in the creation of a Bee Health & Honey R&D division for Meluka Health.

Meluka Health is delighted to have secured such a well-respected person as Dr. Rudd, who has conducted over 8 years of natural product research with an emphasis on natural product chemistry for bioactivity testing in cell studies and animal disease models. He has worked on the development of anti-inflammatory and chemo-preventative natural products as well as research into the efficacy of anti-diabetic medications at Flinders University and Southern Cross University. Dr. Rudd's specialisation includes creating novel analytical methods for the discovery of new natural product candidates from botanical and marine extracts, as well as investigating traditional remedies, where little is known about the chemical ingredients in these traditional preparations. Recent projects have seen David collaborate with apicultural specialists to investigate alternative and organic honey production methods, with the aim of improving European honeybee health - creating mutually beneficial agricultural production systems.

Dr Rudd, said:

"There is an increasing global awareness of the impact that bee health can have on agricultural production systems and maintaining terrestrial biodiversity through pollination services. Fortunately, nature has introduced medicinal properties within those pollination systems, which we aim to harness from Melaleuca old growth plantations. Meluka Health is positioning itself to develop mutually beneficial products that help manage bee health impacts from honey production and I am enthusiastic about assisting them in this pursuit."

Around a third of global food supply comes from bee pollination however global bee populations are declining caused by bee health issues and a solution is required to address this significant problem.

Eve's Investment Director Ben Rohr said:

"Eve is excited to have someone of David's calibre join the Meluka Health team. His expertise will be a valuable addition in the continued development and commercialisation of these unique honey and bee health products"

Conditions Precedent Extension

Both Eve and Meluka Health continue to work to complete the remaining conditions precedent to the transaction and both parties have agreed to extend the conditions precedent deadline until 15 November 2017.

About Meluka Health

Meluka Health is a wellness and nutrition company that develops and sells its naturally derived, organic and ecologically pure products created using its old growth Australian Melaleuca tea tree plantation which are worldly acclaimed for their medicinal activity. Meluka Health is currently focused on producing high quality organic medicinal honey and the development of a bee health tonic.

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in medical nutrition companies. EVE is an investment partner that wants to help build ground breaking and enduring technology with a preference for companies that have global scale.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

For more information:

Ben Rohr
Investment Director
+61 8 6465 5500
benr@eveinvestments.com.au